Literature DB >> 35731312

BRCA1, BRCA2, TP53, PIK3CA, PTEN and AKT1 genes mutations in Burkina Faso breast cancer patients: prevalence, spectrum and novel variant.

Serge Yannick Ouedraogo1,2, Abdou Azaque Zoure2,3, Moutanou Modeste Judes Zeye2,4, Touwendpoulimdé Isabelle Kiendrebeogo2, Xi Zhou1, Alexis Yobi Sawadogo5, Jacques Simpore2, Hanchun Chen6.   

Abstract

BRCA1 and BRCA2 are the two most commonly mutated tumor suppressor genes associated with hereditary breast cancer (BC). Also, mutations in TP53, PIK3CA, PTEN and AKT1 were observed at a high frequency in BC with their mutation spectrum exhibiting a subgroup particularity with enormous clinical significance in the prevention, classification and treatment of cancers. Unfortunately, the mutation spectrum of these genes is still unknown in most Sub-Saharan African population. Therefore, using samples from 133 unselected BC patients, we aimed to assess the contribution of these mutations by direct Sanger sequencing. The analysis revealed pathogenic germline variants on BRCA1 exon 11 (c.3331C > T, 0.75%) and BRCA2 exon 11 (c.5635G > T, c.6211delA; 1.5%). Five other pathogenic variants were identified in 61 of the 133 subjects (45.86%), with 39.09% for PIK3CA, 12.78% for TP53. Interestingly, a variant in PIK3CA found in high frequency in our population was different from the one usually found in other populations (c.1634A > C, 38.34%), and four patients carried mutations linked to Cowen Syndrome 5 c.[1634A > C;1658_1659delGTinsC]. A novel variant (c.312G > T) was found in TP53 gene at 12.78%. Overall, mutation carriers were found more in Her2 negative and in patients that underwent surgery and chemotherapy. No pathogenic variant was found in PTEN and AKT1. Our population displayed a high frequency of PIK3CA mutations with an unusual distribution and spectrum as well as a relatively low prevalence of BRCA mutations. Our results provided novel data on an unstudied population and may help in prevention, and the establishment of suitable therapeutic approaches for our population.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Breast cancer; Burkina Faso; Pathogenic variant; Prevention; Sanger sequencing

Mesh:

Substances:

Year:  2022        PMID: 35731312     DOI: 10.1007/s00438-022-01914-1

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   2.980


  41 in total

1.  Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.

Authors:  Sandrine Boyault; Youenn Drouet; Claudine Navarro; Thomas Bachelot; Christine Lasset; Isabelle Treilleux; Eric Tabone; Alain Puisieux; Qing Wang
Journal:  Breast Cancer Res Treat       Date:  2011-04-22       Impact factor: 4.872

2.  Cancer-specific mutations in PIK3CA are oncogenic in vivo.

Authors:  Andreas G Bader; Sohye Kang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.

Authors:  Xinyi Chen; Yonghai Guo; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Ye Xu; Yuntao Xie
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-26       Impact factor: 4.553

4.  Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.

Authors:  J Abugattas; M Llacuachaqui; Y Sullcahuaman Allende; A Arias Velásquez; R Velarde; J Cotrina; M Garcés; M León; G Calderón; M de la Cruz; P Mora; R Royer; J Herzog; J N Weitzel; S A Narod
Journal:  Clin Genet       Date:  2014-10-28       Impact factor: 4.438

5.  Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.

Authors:  Sangeet Bhaumik; Firoz Ahmad; Bibhu Ranjan Das
Journal:  Med Oncol       Date:  2016-09-16       Impact factor: 3.064

6.  BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors.

Authors:  Khalid Dafaallah Awadelkarim; Gitana Aceto; Serena Veschi; Ahmed Elhaj; Annalisa Morgano; Ahmed Abdalla Mohamedani; Elgaylani Abdalla Eltayeb; Dafaallah Abuidris; Mario Di Gioacchino; Pasquale Battista; Fabio Verginelli; Alessandro Cama; Nasr Eldin Elwali; Renato Mariani-Costantini
Journal:  Breast Cancer Res Treat       Date:  2007-03-01       Impact factor: 4.872

7.  Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer.

Authors:  Orland Diez; Amadeu Pelegrí; Neus Gadea; Sara Gutiérrez-Enríquez; Miriam Masas; Anna Tenés; Nina Bosch; Judith Balmaña; Begoña Graña
Journal:  Oncol Lett       Date:  2011-08-19       Impact factor: 2.967

8.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

9.  Analysis of PIK3CA mutations in breast cancer subtypes.

Authors:  Ruza Arsenic; Annika Lehmann; Jan Budczies; Ines Koch; Judith Prinzler; Anke Kleine-Tebbe; Christiane Schewe; Sibylle Loibl; Manfred Dietel; Carsten Denkert
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-01

10.  Expression of tumor necrosis factor-alpha-mediated genes predicts recurrence-free survival in lung cancer.

Authors:  Baohua Wang; Ning Song; Tong Yu; Lianya Zhou; Helin Zhang; Lin Duan; Wenshu He; Yihua Zhu; Yunfei Bai; Miao Zhu
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.